Everything below concerns size-exclusion HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
While American slaves in the Antebellum South were sold for around $40,000 (in inflation adjusted dollars), a slave nowadays can be bought for just $90, making replacement more economical than providing long-term care. Slavery is a multibillion-dollar industry with estimates of up to $35 billion generated annually.
Sponsors Boy and Girl Scout troops, Red Cross, various parish functions, church retreats, visits the sick and assists the needy, sponsors masses; and supports students studying theology and Catholic educational activities. Merged into the First Catholic Slovak Ladies Association in 2004. Knights of Columbus Knights of Peter Claver - Founded in 1909 by members of Most Pure Heart of Mary Catholic Church in Mobile, Alabama, as a Black Catholic fraternal order, as Blacks were barred from the Knights of Columbus due to their race. Among the founders were The Rev. John H. Dorsey (the second Black Catholic priest ordained in the US), many White priests, and three Black parishioners. Knights of St. John - Founded in 1879. Membership is open to "practical Catholic gentlemen" ages 16–55. Social membership available was also available, even to those over 55. In 1978 there were 7,144 members. The international structure is called the "Supreme Commandery", regional structures "Grand Commanderies", and local units are called "Commanderies". There were 172 Commanderies in 1978 including 27 in "West Africa", 5 in Togo, and 8 in Trinidad and Tobago. The order has a secret ritual but dropped password in April 1977 because it was time-consuming and had "no appreciable organizational value". The group appears in uniforms for Catholic ceremonies such as first communions Masses, and confirmations. The order has a sports program that sponsors golf and bowling. There is also a death benefit.
== History == Flucloxacillin was developed in the 1960s, following an increase in penicillin-resistant (beta-lactamase producing) staphylococcal infections, due to the widespread use of benzylpenicillin by 1960. All the natural penicillins and first semi-synthetic penicillins were destroyed by staphylococcal beta-lactamase, leading Beecham (later GlaxoSmithKline) to search for more stable antibiotics. By 1962, a series of similarly structured acid-stable penicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), with the potential for being taken by mouth, were developed. Flucloxacillin and dicloxacillin showed particular stability against the beta-lactamase enzyme of Staph. aureus and could withstand acid. Beecham further developed cloxacillin and popularised flucloxacillin in the UK, while Bristol Laboratories concentrated on marketing oxacillin and dicloxacillin in the United States, leading to the difference in use in each country. Flucloxacillin was first marketed in Europe in the 1970s.
=== Automation === In the past, oligonucleotide synthesis was carried out manually in solution or on solid phase. The solid phase synthesis was implemented using, as containers for the solid phase, miniature glass columns similar in their shape to low-pressure chromatography columns or syringes equipped with porous filters. Currently, solid-phase oligonucleotide synthesis is carried out automatically using computer-controlled instruments (oligonucleotide synthesizers) and is technically implemented in column, multi-well plate, and array formats. The column format is best suited for research and large scale applications where a high-throughput is not required. Multi-well plate format is designed specifically for high-throughput synthesis on small scale to satisfy the growing demand of industry and academia for synthetic oligonucleotides.
The bloom strength of a gelatine mixture is the measure of how strong it is. It is defined by the force in grams required to press a 12.5 mm (0.49 in) diameter plunger 4 mm (0.16 in) into 112 g (4.0 oz) of a standard 6.67% w/v gelatine gel at 10 °C (50 °F). The bloom strength of a gel is useful to know when determining the possibility of substituting a gelatine of one bloom strength for a gelatine of another. One can use the following equation:
Sources: en.wikipedia.org
Long-term risks include mania and heart issues such as long QT syndrome, and potentially fatal interactions with other drugs. Only two randomized controlled trials have been conducted on ibogaine and noribogaine for substance use disorders, and while they show preliminary anti-addictive potential, their safety and efficacy are unconfirmed, with significant risks including cardiotoxicity and fatalities. Ibogaine is federally illegal in the United States. It is used in treatment clinics abroad under legal gray areas, with growing media attention. It has inspired the development of non-hallucinogenic, non-cardiotoxic analogues like 18-MC and tabernanthalog for therapeutic use. In 2025, Texas allocated $50 million for clinical research on ibogaine to develop FDA-approved treatments for opioid use disorder, co-occurring substance use disorders, and other ibogaine-responsive conditions. A 2026 US executive order directed federal agencies to accelerate review of ibogaine.
Following the House passage of OBBBA, the bill moved to the Senate for consideration. The Republican-led Senate amended the bill. Fiscally conservative Republican Senators (nicknamed "deficit hawks") such as Ron Johnson of Wisconsin, Rick Scott of Florida, Mike Lee of Utah, and Rand Paul of Kentucky, pushed for deeper spending cuts. Moderate Republicans such as Susan Collins of Maine, Lisa Murkowski of Alaska, and Jerry Moran of Kansas, along with populist Josh Hawley of Missouri, expressed concerns about Medicaid cuts. Other moderates such as John Curtis of Utah and Thom Tillis of North Carolina, along with Murkowski and Moran, expressed concerns over the end of green energy tax credits. Defense hawks such as Mike Rounds of South Dakota were opposed to spectrum auction provisions in the bill. Democrats in the Senate sought to use the Byrd Rule, which prevents reconciliation from being used to pass "extraneous" measures in bills which increase federal spending in the Senate, in order to strip certain provisions from the bill. Democrats argued that the extension of Trump's 2017 tax cuts, a proposed 10-year ban on state level AI regulations, language that limits the power of federal court to enforce contempt of court citations, a provision to end a tax on the manufacturing of gun silencers, a provision to defund Planned Parenthood, a provision banning Medicaid from funding gender-affirming care for people of all ages and a provision to streamline permits for fossil fuel projects, violated the Byrd Rule.
=== USDS Joint Venture, censorship, backlash and moves to UpScrolled === On 22 January 2026, US President Donald Trump and TikTok announced that the company had joined a joint venture, which will run as an independent entity while operating under defined safeguards that protect national security for US users. Adam Presser who was previously TikTok's head of operations and trust and safety will serve as CEO, while TikTok's current CEO Shou Chew will be a director of the new venture. The new investors are loyal to Trump. TikTok has subsequently been accused of censoring content critical of Trump and his administration. The censorship includes censoring words such as "Epstein" and videos that criticize Trump or Immigration and Customs Enforcement (ICE). The resulting backlash saw TikTok competitor UpScrolled receive record downloads and rise to second in the Apple's App Store rankings.
== Modifications == The threonine residue is susceptible to numerous posttranslational modifications. The hydroxyl side-chain can undergo O-linked glycosylation. In addition, threonine residues undergo phosphorylation through the action of a threonine kinase. In its phosphorylated form, it can be referred to as phosphothreonine. Phosphothreonine has three potential coordination sites (carboxyl, amine and phosphate group) and determination of the mode of coordination between phosphorylated ligands and metal ions occurring in an organism is important to explain the function of the phosphothreonine in biological processes.
==== Sublabial ==== Sublabial administration is achieved by placing the drug between the lip and gum. The frenulum of the tongue may be irritated when in contact with corrosive materials but can be avoided with this route. It is usually used for medications such as nitroglycerin, for example.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.